Abstract
Urine represents the most easily obtainable body fluid and consequently one of the most common samples in clinical chemistry. The majority of pathological changes in human organs may well be reflected in urine. In this way, urine analysis can aid in disease diagnosis, treatment monitoring, and prognosis. Currently, the most commonly used method for identification of new urine biomarkers involves centrifugation of the urine sample to collect either the soluble urine proteins or the urinary exosomes followed by 1 or 2 protein purification and separation steps before visualization and finally identification of potential biomarkers, usually by mass spectrometry.
Here we present a generally applicable, rapid, and robust method for screening large number of urine samples, resulting in a broad spectrum of native peptides, as a tool to be used for biomarker discovery. The method combines online sample pretreatment with a well-established mass spectrometric technique. Native peptides are extracted from urine samples on a miniaturized reverse-phase–strong cation exchange cartridge system. As the proper identification of native peptides often requires combination of data acquired on different mass analyzers, we have aimed at a procedure providing us with sufficient material to identify and characterize the differentially expressed markers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572–577
Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr (2002) Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62:3609–3614
De Noo ME, Deelder A, van der Werff M, Ozalp A, Mertens B, Tollenaar R (2006) MALDI-TOF serum protein profiling for the detection of breast cancer. Onkologie 29:501–506
De Noo ME, Mertens BJ, Ozalp A, Bladergroen MR, van der Werff MP, van de Velde CJ, Deelder AM, Tollenaar RA (2006) Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur J Cancer 42:1068–1076
Rai AJ, Zhang Z, Rosenzweig J, Shih I, Pham T, Fung ET, Sokoll LJ, Chan DW (2002) Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 126:1518–1526
Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone DP (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362:433–439
Davidsson P, Sjogren M (2005) The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers 21:81–92
Gineste C, Ho L, Pompl P, Bianchi M, Pasinetti GM (2003) High-throughput proteomics and protein biomarker discovery in an experimental model of inflammatory hyperalgesia: effects of nimesulide. Drugs 63(Suppl 1):23–29
Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright JG Jr (2001) Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. American Journal of Pathoogy 158:1491–1502
Hortin GL, Sviridov D (2007) Diagnostic potential for urinary proteomics. Pharmacogenomics 8:237–255
Kim MK, Warren TC, Kimball ES (1985) Purification and characterization of a low molecular weight transforming growth factor from the urine of melanoma patients. J Biol Chem 260:9237–9243
Meng QC, Balcells E, Dell’Italia L, Durand J, Oparil S (1995) Sensitive method for quantitation of angiotensin-converting enzyme (ACE) activity in tissue. Biochem Pharmacol 50:1445–1450
Sato K, Hirata Y, Imai T, Iwashina M, Marumo F (1995) Characterization of immunoreactive adrenomedullin in human plasma and urine. Life Sci 57:189–194
Walters AE, Myrdal PB, Pinsuwan S, Manka AM, Yalkowsky SH (1997) Determination of melanotan II in rabbit urine using solid-phase extraction sample preparation followed by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 690:99–103
Fierens C, Thienpont LM, Stockl D, Willekens E, De Leenheer AP (2000) Quantitative analysis of urinary C-peptide by liquid chromatography-tandem mass spectrometry with a stable isotopically labelled internal standard. J Chromatogr A 896:275–278
Sanchez JC, Hochstrasser DF (1999) Preparation and solubilization of body fluids for 2-D. Methods Mol Biol 112:87–93
McKee JA, Kumar S, Ecelbarger CA, Fernandez-Llama P, Terris J, Knepper MA (2000) Detection of Na(+) transporter proteins in urine. J Am Soc Nephrol 11:2128–2132
Thongboonkerd V, McLeish KR, Arthur JM, Klein JB (2002) Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 62:1461–1469
Marshall T, Williams KM (1998) Clinical analysis of human urinary proteins using high resolution electrophoretic methods. Electrophoresis 19:1752–1770
Cutler P, Bell DJ, Birrell HC, Connelly JC, Connor SC, Holmes E, Mitchell BC, Monte SY, Neville BA, Pickford R, Polley S, Schneider K, Skehel JM (1999) An integrated proteomic approach to studying glomerular nephrotoxicity. Electrophoresis 20:3647–3658
Ostergaard M, Wolf H, Orntoft TF, Celis JE (1999) Psoriasin (S100A7): a putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. Electrophoresis 20:349–354
Heine G, Raida M, Forssmann WG (1997) Mapping of peptides and protein fragments in human urine using liquid chromatography-mass spectrometry. J Chromatogr A 776:117–124
Cutillas PR, Norden AG, Cramer R, Burlingame AL, Unwin RJ (2003) Detection and analysis of urinary peptides by on-line liquid chromatography and mass spectrometry: application to patients with renal Fanconi syndrome. Clinical Science (London) 104:483–490
Hughes NC, Wong EY, Fan J, Bajaj N (2007) Determination of carryover and contamination for mass spectrometry-based chromatographic assays. The American Association of Pharmaceutical Scientists journal 9:E353–E360
Balog CI, Hensbergen PJ, Derks R, Verweij JJ, van Dam GJ, Vennervald BJ, Deelder AM, Mayboroda OA (2009) Novel automated biomarker discovery work flow for urinary peptidomics. Clin Chem 55:117–125
Beavis RC, Chaudhary T, Chait BT (1992) Alpha-cyano-4-hydroxycinnamic acid as a matrix for matrix-assisted laser desorption mass-spectrometry. Organic Mass Spectrometry 27:156–158
Acknowledgments
This study was supported by the European Union, Sixth framework program, Specific Measures in support of International Cooperation (INCO), contract 517733.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this protocol
Cite this protocol
Balog, C.I.A., Derks, R., Mayboroda, O.A., Deelder, A.M. (2013). An Automated RP–SCX Solid-Phase Extraction Procedure for Urinary Peptidomics Biomarker Discovery Studies. In: Bäckvall, H., Lehtiö, J. (eds) The Low Molecular Weight Proteome. Methods in Molecular Biology, vol 1023. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7209-4_11
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7209-4_11
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7167-7
Online ISBN: 978-1-4614-7209-4
eBook Packages: Springer Protocols